Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, denosumab (Xgeva®) cannot be endorsed for use within NHS Wales for the prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with multiple myeloma. |
||
|
||
Medicine details |
||
| Medicine name | denosumab (Xgeva®) | |
| Formulation | 120 mg solution for injection | |
| Reference number | 1351 | |
| Indication | Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with multiple myeloma. |
|
| Company | Amgen Ltd | |
| BNF chapter | Musculoskeletal & joint diseases | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 23/07/2018 | |